New Product Shines at NCLM — Shanghai Sunbio Ushers in a Breakthrough Moment

From October 30 to November 1, Jinan hosted the annual grand event of the clinical laboratory industry — the 19th National Conference on Laboratory Medicine (NCLM) organized by the Chinese Society of Laboratory Medicine. Nearly ten thousand professionals in laboratory medicine gathered in the “Spring City” to discuss cutting-edge topics such as the standardization of hemostasis testing, smart laboratory development, and clinical molecular diagnostics.

At this academicevent , Shanghai Sunbio showcased its latest advancements in the field of coagulation testing. Following the development of its comprehensive product portfolio comprising the UP, UR, and UG series coagulation analyzers and the UL-2000LAS automated line, SUNBIO is now experiencing a breakthrough moment in special coagulation assays. The company presented a series of reagents including Protein C, Coagulation Factors II, V, VII, VIII, IX, X, XI, XII, Anti-Xa, and LA — assays that were once heavily dependent on imported products. Today, laboratories can now benefit from high-quality, cost-effective domestic alternatives developed by Shanghai Sunbio.

 Several distinguished experts visited the Shanghai Sunbio booth during the exhibition to learn about the company’s latest developments in coagulation testing. These included:

 Professor Wang Chuanxin, Chair of the Hematology Laboratory Medicine Branch of the Chinese Society of Laboratory Medicine, Shandong University Qilu Hospital.

Professor Cui Wei, incoming Chair of the Hematology Laboratory Medicine Branch of the Chinese Society of Laboratory Medicine, Cancer Hospital, Chinese Academy of Medical Sciences.

Professor Guan Ming from Huashan Hospital, Fudan University.

Professor Pan Shiyang of theJiangsu Provincial People’s Hospital.

Professor Ou Qishui of the First Affiliated Hospital of Fujian Medical University.

Professor Cong Yulong, the former Chair of the 5th and 6th Hematology Laboratory Medicine Branches of the Chinese Society of Laboratory Medicine.

Professor Wang Xuefeng of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.

These experts took a detailed look at Sunbio’s latest R&D achievements in coagulation testing and expressed a great deal of interest and full recognition of the company’s series of technological breakthroughs.

Advances in Coagulation Research Reflect Real Clinical Needs

The session on the standardization of hemostasis testing, chaired by Professor Wang Xuefeng from Ruijin Hospital, Shanghai Jiao Tong University, brought together leading domestic medical institutions to present the latest coagulation testing research.

A key focus of the discussions was the standardized diagnosis of thrombotic disorders. Professor Dai Jing also from Ruijin Hospital has conducted in-depth studies on prothrombin in bleeding and thrombotic diseases, revealing that prothrombin gene mutations are important hereditary risk factors for venous thromboembolism (VTE), and exploring the clinical application of mutant prothrombin as a novel hemostatic material in bleeding disorders.Additionally, Professor Chen Changming conducted a comprehensive study on antithrombin deficiency within a large Chinese cohort of families predisposed to thrombosis. His research identified four pathogenic SERPINC1 variants, providing crucial insights for the precise diagnosis of thrombotic disorders.

The standardization of coagulation factor testing has also attracted significantattention. Professor Zhang Zhenfei from Zhujiang Hospital, Southern Medical University presentedhis research intoestablishing reference intervals for plasminogen, Factor XII activity, and Factor XIII antigen in the Chinese population. Professor Mu Danni from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, used an indirect method to establish reference intervals for four coagulation parameters in high-altitude Chinese populations. Meanwhile, Professor Wang Yuhua from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, applied clot waveform analysis to improve the precise classification and diagnosis of fibrinogen abnormalities.

Another important topic was Precision Monitoring of Anticoagulant Therapy . Professor Zhang Mingyang systematically investigated the performance differences of various detection systems in monitoring rivaroxaban anti-Xa activity.

A series of studies from frontline clinical laboratories has shown that a comprehensive system for special coagulation assays is essential for supporting clinical practice — from screening for thrombosis risk to monitoring anticoagulants, diagnosing coagulation factor deficiencies  and providing arapid response in critical and severe cases.

Understanding Clinical Needs: New Breakthroughs in Special Coagulation Assays

Driven by a deep understanding of clinical needs, Shanghai Sunbio continues to innovate in the field of coagulation testing. From the UP5500 being selected for the Outstanding Domestic Medical Devices Catalogue, to the UG2500 optical-mechanical integrated coagulation analyzer that combines platelet aggregation and coagulation testing, from the UR6000 and UR8000 ultra-high-speed coagulation analyzers continuously setting new benchmarks for detection speed, and the UL-2000LAS an automated line providing a complete smart coagulation testing solution. These products have established the company as a leading provider of high-end coagulation testing equipment. At the same time, the company’s significant achievements in thrombosis risk screening, coagulation factor testing, and anticoagulant therapy monitoring reflect its deep technological expertise and leadership in the field of coagulation.

This is not a sudden breakthrough — but the Inevitable Result of Years of Accumulated Expertise. From instruments to reagents, from speed to accuracy, and from routine assays to special coagulation tests, Shanghai Sunbio has, through continuous technological innovation and clinical research, provided medical institutions with high-quality, cost-effective domestic alternatives. This has promoted the standardized implementation of special coagulation assays — including thrombosis risk screening, coagulation factor deficiency testing, and anticoagulant therapy monitoring — in more healthcare facilities.

The autumn in Jinan witnessed another exchange of ideas in the field of laboratory medicine and marked Shanghai Sunbio’s latest breakthroughs in coagulation testing. Through concrete actions, the company is living up to its mission of “Creating Products for Life”, thereby supporting the high-quality development of laboratory medicine in China.

About Shanghai Sunbio

Founded in 2001, Shanghai Sun Biotech Co.,Ltd. specializes in the field of thrombosis and hemostasis diagnostics and is a leading global provider of comprehensive solutions in this domain.Guided by the mission of “Creating Products for Life”, the company is dedicated to the research, development, production, and sales of thrombosis and hemostasis diagnostic reagents, medical instruments, and consumables.

Shanghai Sunbio strictly adheres to quality management systems and has obtained ISO 9001 and ISO 13485 dual international quality certifications. All core products are protected by independent intellectual property rights, with more than 100 patents granted. The company actively participates in the development of national industry standards for PT, APTT, TT, FIB, D-Dimer, anti-Xa, and coagulation analyzers, promoting the standardization of coagulation testing technologies. Shanghai Sunbio has been recognized with multiple honors, including “Specialized and New ‘Little Giant’ Enterprise” by the Ministry of Industry and Information Technology, National High-Tech Enterprise, Shanghai Science & Technology Little Giant Enterprise, and Shanghai Intelligent Factory, among others.

Looking ahead, Shanghai Sunbio will continue to deepen its expertise in thrombosis and hemostasis diagnostics, uphold technology-driven innovation for product advancement, and continuously provide professional coagulation diagnostic solutions to global customers, contributing to the development of healthcare worldwide.